SBIR Phase I: A high throughput microfluidic platform to accelerate biomanufacturing transitions in the COVID-19 response

这项小型企业创新研究（SBIR）第一阶段项目的更广泛影响/商业潜力旨在应对应对COVID-19的关键挑战，即生产足够数量的新型疗法和疫苗。该项目可以将药物的开发时间缩短6个月，加速新疗法的转化。这项技术还将使更多的测试，从而提高性能，并可能减少这些药物的副作用。SBIR第一阶段项目推进了生物制剂的生产，从单细胞衍生的高性能克隆细胞系开始（根据定义）。今天，开发这样的细胞系需要长达6个月的时间，因为需要反复筛选和测试，以确保质量和性能。该项目旨在通过使用专有的单细胞蛋白质组学平台，以前所未有的吞吐量，而不是冗长的迭代选择，克隆扩增和分析，在一天内选择出高性能的细胞克隆，而不是几个月。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project aims to address a key challenge in the response to COVID-19, namely manufacturing sufficient quantities of novel therapeutics and vaccines. This project can shorten the development times of drugs by as much as 6 months, accelerating translation of new therapeutics. This technology will also enable more testing, thereby increasing the performance and potentially reducing the side effects of these drugs.This SBIR Phase I project advances the manufacturing of biologics, which starts with a high performing clonal cell line derived (by definition) from a single cell. Developing such a cell line today takes up to 6 months due to iterative screening and testing to assure quality and performance. The proposed project aims to enable selection of a high performing cell clone in one day compared to many months by using a proprietary single cell proteomics platform, at an unprecedented throughput rather than lengthy, iterative selection, clonal expansion and analytics.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.